Himalaya Nutravedics India IPO Day 1: GMP ₹0

Well, the much-anticipated Himalaya Nutravedics India SME IPO on the BSE has officially opened its doors for subscriptions today, September 22, 2026. For Day 1, the subscription figures are looking precisely as they did yesterday – a clean slate across all categories. This means no bids have come in yet for the Retail, Non-Institutional Investor (NII), or Qualified Institutional Buyer (QIB) segments. It’s still very early days, of course, but it’s always interesting to see how the first day unfolds.

Subscription Status

Let’s break down what this initial zero subscription across the board actually signifies. When an IPO opens, it’s common for the initial hours, or even the first day, to see a slow uptake. This is particularly true for SME IPOs which often gather momentum as the subscription period progresses. The absence of bids in the Retail, NII, and QIB categories right now doesn’t necessarily spell doom. It could simply mean investors are taking their time, evaluating the company and the market conditions.

For QIBs, their participation is usually a strong indicator of institutional confidence. Their absence on Day 1 is something to watch, but not a cause for immediate alarm. Similarly, NIIs, who invest larger sums, often wait to see how the retail segment responds before committing. The Retail segment, which comprises individual investors applying for smaller lots, is typically the first to show activity. Their current zero subscription is the most notable observation from today’s update. We’ll need to see a significant shift in these numbers over the next two days to gauge investor interest more accurately.

GMP Update

Now, let’s talk about the Grey Market Premium (GMP). For Himalaya Nutravedics India IPO, the GMP remains at ₹0. This is the same as it was yesterday, indicating no premium or discount is currently being factored in by the grey market. An IPO with a GMP of ₹0 suggests that the market perception, as reflected in the unofficial grey market, is currently aligned with the issue price of ₹106. This means investors in the grey market aren’t expecting a significant listing gain right now.

The expected listing price of ₹106, matching the issue price, reinforces this sentiment. While a ₹0 GMP might seem unexciting, it also means there’s no negative sentiment attached to the IPO at this stage. It’s a neutral stance, and the actual listing performance will heavily depend on how the subscription numbers shape up and the company’s fundamentals. We’ll be keeping a close eye on any changes in the GMP as the subscription period continues.

Should You Apply?

So, the big question: should you be applying for Himalaya Nutravedics India’s IPO based on today’s Day 1 update? It’s a bit of a mixed bag, and a decision requires careful consideration. On one hand, the zero subscription numbers on Day 1 and the ₹0 GMP suggest that there isn’t overwhelming immediate demand or a strong expectation of listing gains. This could present an opportunity for those who believe in the company’s long-term prospects and are looking to invest at or near the issue price. The lot size is 1200 shares, so keep that in mind for your investment calculation.

However, it’s crucial to remember that this is just Day 1. The subscription period runs until September 24, 2026. A lot can change in the next two days. Investors often wait until the last day or two to place their bids, especially in SME IPOs. The SEBI advisor would likely suggest thoroughly researching the company’s business model, financial health, and future growth potential before making any investment decision. Don’t solely rely on GMP or Day 1 subscription figures. The bottom line is, if you’re looking for quick listing gains, the current sentiment might not be the most encouraging. But if you’re a long-term investor with conviction in Himalaya Nutravedics India, this could be a period of observation before making your move.

View Full Himalaya Nutravedics India IPO Details